Maravai LifeSciences Holdings's ROE % for the quarter that ended in Mar. 2026 was -7.05%. Maravai LifeSciences Holdings's PB Ratio for the quarter that ended in Mar. 2026 was 3.29.
Maravai LifeSciences Holdings's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -2.14%.
Maravai LifeSciences Holdings ROE % Adjusted to Book Value Related Terms
Maravai LifeSciences Holdings ROE % Adjusted to Book Value Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maravai LifeSciences Holdings ROE % Adjusted to Book Value Chart
MEX:MRVI vs LBRX, SLDB, JANX: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Maravai LifeSciences Holdings's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maravai LifeSciences Holdings ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Maravai LifeSciences Holdings's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Maravai LifeSciences Holdings's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -2.14% mean?
Maravai LifeSciences Holdings (MEX:MRVI) has a ROE % Adjusted to Book Value of -2.14% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Maravai LifeSciences Holdings and its competitors.
Is Maravai LifeSciences Holdings' ROE % Adjusted to Book Value too high?
Maravai LifeSciences Holdings' current ROE % Adjusted to Book Value is -2.14%. Overall, Maravai LifeSciences Holdings has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Maravai LifeSciences Holdings' ROE % Adjusted to Book Value compare to LBRX and SLDB?
Maravai LifeSciences Holdings' ROE % Adjusted to Book Value of -2.14% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Maravai LifeSciences Holdings and its competitors. Maravai LifeSciences Holdings's current ROE % Adjusted to Book Value is -2.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maravai LifeSciences Holdings stock overvalued right now?
Maravai LifeSciences Holdings (MEX:MRVI) has a current ROE % Adjusted to Book Value of -2.14%. The stock's GF Value™ is MXN52.80, compared to a current price of MXN85.00 — trading 61% above its estimated fair value. The current ROE % Adjusted to Book Value is -2.14%. Maravai LifeSciences Holdings' overall GF Score™ is 62/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Maravai LifeSciences Holdings (MEX:MRVI), the current ROE % Adjusted to Book Value is -2.14% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maravai LifeSciences Holdings (MEX:MRVI) Overvalued in 2026?
Based on GuruFocus' analysis, Maravai LifeSciences Holdings stock appears to be overvalued.
The current stock price of MXN85.00 is trading 61% above its estimated GF Value™ of MXN52.80.
Key valuation signals for MEX:MRVI:
ROE % Adjusted to Book Value: -2.14%
GF Value™: MXN52.80 vs. price of MXN85.00 (61% above fair value)
No single metric tells the full story. See the MEX:MRVI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maravai LifeSciences Holdings Business Description
Maravai LifeSciences Holdings Inc is a life sciences company providing products and services to enable the development of drugs, therapeutics, vaccines and diagnostics, and to support research on human disease. Its product portfolio includes complex nucleic acids, custom enzymes and antibody-based solutions for therapeutic, vaccine, diagnostic and biopharmaceutical production applications. The Company operates through two segments: TriLink, which generates maximum revenue from North America and provides nucleic acid products and services including mRNA, oligonucleotides and related technologies; and Cygnus, which provides biologics safety testing products and services including host cell protein ELISA kits, impurity detection assays and related reagents and services.
62GF Score
Get the complete analysis for MEX:MRVI
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:MRVI has been successfully added to your 
